For more than 25 years, lab-on-a-chip technology has allowed researchers to model human organs and blood vessels using real ...

Even for those of us that are quite technically minded, we spend precious little time thinking about the cables that carry ...

With the aid of physical forces—in this case, sound—it is possible to actively steer the formation of engineered tissue. For ...

Google didn't forget AI creators in its latest round of Gemini announcements as part of Google I/O. The company just officially revealed Gemini Omni, a new model that can "create anything from any ...

It used to be easy enough to distinguish between human-made and AI-generated imagery — just two years ago, you couldn’t use image models to create a menu for a Mexican restaurant without inventing new ...

SunZia has quietly begun sending enormous amounts of wind power to California, as President Donald Trump works to thwart the wind industry. The largest renewable energy project ever built in the ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

The Federal Reserve's pause on rate cuts means investors can still grab attractive yields on short-duration assets. The central bank opted to keep the federal funds rate between 3.5% to 3.75% on ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...